Defining key outcomes to evaluate performance of newborn screening programmes for cystic fibrosis
Anne Munck1, Kevin W Southern2, Carlo Castellani3
1CF referent physician for the French Society of Newborn Screenings, Hospital Necker Enfants-Malades, AP-HP, CF centre, Université Paris Descartes, France.
Abstract
No abstract available in PubMed .
More Related Videos
09:47Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD
Published on: September 13, 2018
16.9K
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
7.3K
Related Concept Videos
Cystic Fibrosis: Pathogenesis
542
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
542
Cystic Fibrosis: Management
310
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
310
